Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

被引:75
作者
Wahlin, A
Markevärn, B
Golovleva, I
Nilsson, M
机构
[1] Umea Univ, Dept Med, Sect Haematol, Umea, Sweden
[2] Umea Univ, Dept Clin Genet, S-90187 Umea, Sweden
关键词
acute myeloid leukaemia; cytogenetics; age; survival; prognosis;
D O I
10.1046/j.1365-2141.2001.03043.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prognostic factors were studied in a series of 211 acute myeloid leukaemia (AML) patients over 60 years of age, treated at a single centre. The patients were allocated into three risk groups based on cytogenetics, occurrence of antecedent haematological disorder and leucocyte count. Only 3% had low-risk features, 39% had intermediate- and 58% had adverse-risk features. Complete remission (CR) was achieved in 43% of all patients. In multivariate analyses, the number of cycles needed to achieve CR and the risk group were significantly associated with the duration of CR. Median survival time for the entire cohort of patients was only 107 d. Advanced age, low induction treatment intensity; treatment during earlier years and adverse-risk group were associated with shorter overall survival times. Risk group classification may help selection of elderly patients with a good chance of benefiting from intensive treatment to actually receive such treatment, while sparing others with a low probability of survival benefit from toxic treatment. Low intensity induction treatment reduces the chance of obtaining complete remission, produces inferior survival times and should consequently be avoided when the aim is to obtain complete remission. In elderly AML patients, introducing age and re-evaluation of intermediate and good prognosis patients regarding response to induction treatment may improve the risk group classification.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 22 条
[1]  
ARLIN ZA, 1991, SEMIN HEMATOL, V28, P44
[2]   THE CLINICAL-SIGNIFICANCE OF KARYOTYPE IN ACUTE MYELOGENOUS LEUKEMIA [J].
ARTHUR, DC ;
BERGER, R ;
GOLOMB, HM ;
SWANSBURY, GJ ;
REEVES, BR ;
ALIMENA, G ;
VANDENBERGHE, H ;
BLOOMFIELD, CD ;
DELACHAPELLE, A ;
DEWALD, GW ;
GARSON, OM ;
HAGEMEIJER, A ;
KANEKO, Y ;
MITELMAN, F ;
PIERRE, RV ;
RUUTU, T ;
SAKURAI, M ;
LAWLER, SD ;
ROWLEY, JD .
CANCER GENETICS AND CYTOGENETICS, 1989, 40 (02) :203-216
[3]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[4]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[5]  
Bloomfield CD, 1998, CANCER RES, V58, P4173
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]  
DASTUGUE N, 1995, LEUKEMIA, V9, P1491
[8]   Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age [J].
Deeg, HJ ;
Shulman, HM ;
Anderson, JE ;
Bryant, EM ;
Gooley, TA ;
Slattery, JT ;
Anasetti, C ;
Fefer, A ;
Storb, R ;
Appelbaum, FR .
BLOOD, 2000, 95 (04) :1188-1194
[9]   HYPERLEUKOCYTOSIS IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA - IMPACT ON REMISSION RATE AND DURATION, AND SURVIVAL [J].
DUTCHER, JP ;
SCHIFFER, CA ;
WIERNIK, PH .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1364-1372
[10]   Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB [J].
Estey, EH ;
Shen, Y ;
Thall, PF .
BLOOD, 2000, 95 (01) :72-77